KERRI FLESHIA BEST-SULE
Allopathic & Osteopathic Physicians|Pediatrics PERRY HALL, MD NPI 1104289024
Browse related groups: Allopathic & Osteopathic Physicians|Pediatrics MD GlaxoSmithKline, LLC. All categories
General Payments — all program years on this page
$13,090.74
- Category: General Payments
- Program years: PY2022–2023
- Record count: 19
- As of (CMS publication): 2026-01-23
Latest program year (PY2023): $5,034.90 across 9 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2023) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $5,034.90 | 9 |
By paying entity
Latest program year (PY2023) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $5,034.90 | 9 |
By program year
Records — PY2023 (9)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1001893389 | GlaxoSmithKline, LLC. | $1,006.98 | 01/09/2023 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1001893397 | GlaxoSmithKline, LLC. | $1,006.98 | 01/28/2023 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1001893427 | GlaxoSmithKline, LLC. | $335.66 | 01/23/2023 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1001895087 | GlaxoSmithKline, LLC. | $335.66 | 02/11/2023 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1001896747 | GlaxoSmithKline, LLC. | $167.83 | 03/01/2023 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1001896777 | GlaxoSmithKline, LLC. | $671.32 | 02/10/2023 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1001898619 | GlaxoSmithKline, LLC. | $335.66 | 02/20/2023 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1001900541 | GlaxoSmithKline, LLC. | $839.15 | 01/23/2023 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1001902177 | GlaxoSmithKline, LLC. | $335.66 | 03/06/2023 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.